Down Syndrome – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Down Syndrome is a chromosomal disease characterized by intellectual disability, a distinctive facial appearance, and low muscle tone (hypotonia) in infancy. Although all affected people experience cognitive delays, the intellectual disability is usually mild to moderate. People with DS may have a variety of congenital disabilities. A heart defect affects approximately half of all affected children. Digestive abnormalities, such as intestine blockage, are less common. Individuals with DS are at a higher risk of developing various medical conditions. These include gastroesophageal reflux, a backflow of acidic stomach contents into the esophagus, celiac disease, and gluten intolerance. Trisomy 21 (nondisjunction) is the most ordinary type of Down syndrome, accounting for 95 percent of cases. Babies are typically born with 23 chromosome pairs (or 46 total chromosomes) in each cell, one inherited from the mother and father. In Trisomy 21, an error in cell division is called “nondisjunction” this results in a baby being born with an additional copy of chromosome 21, meaning there are three copies of chromosome 21 instead of the usual two.

The prevalence of Down Syndrome ranges from 80 to 91 cases per 100,000 population in the USA.

 

The competitive landscape of Down Syndrome includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Down Syndrome across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Down Syndrome Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Down Syndrome – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Donepezil HCl   Eisai Inc.          Phase 2

2          ELND005          Elan Pharmaceuticals    Phase 2

3          RG1662            Hoffmann-La Roche      Phase 2
 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033